| |  Online-Ressource |
|---|
| Verfasst von: | Bärtsch, Marc-Andrea [VerfasserIn]  |
|---|
| | Fougereau, Mathilde [VerfasserIn] |
|---|
| | Hielscher, Thomas [VerfasserIn] |
|---|
| | Sauer, Sandra [VerfasserIn] |
|---|
| | Breitkreutz, Iris [VerfasserIn] |
|---|
| | Jordan, Karin [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Raab, Marc-Steffen [VerfasserIn] |
|---|
| | Hillengaß, Jens [VerfasserIn] |
|---|
| | Giesen, Nicola [VerfasserIn] |
|---|
| Titel: | Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma |
|---|
| Verf.angabe: | Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass and Nicola Giesen |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 20 September 2021 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 17.11.2021 ; This article belongs to the special issue "Autologous and allogeneic stem cell transplant in cancer therapy" |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 13(2021), 18, special issue, Artikel-ID 4706, Seite 1-13 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57%) attained ≥ very good partial response (VGPR), which increased to 34/44 (77%) at best response after salvage HDCT/ASCT. Median progression-free survival (PFS) was 23.3 months from salvage HDCT/ASCT. Patients with ≥ VGPR at the time of salvage HDCT/ASCT and those receiving maintenance treatment post salvage HDCT/ASCT had significantly superior PFS (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009). In patients achieving at least an equal depth of response before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS after salvage HDCT/ASCT was comparable to the frontline situation (p = 0.3). This is the first report of state-of-the-art triplet re-induction and salvage HDCT/ASCT for RRMM after frontline transplantation. Deep remissions achieved with KRd translate into prolonged PFS following salvage HDCT/ASCT and are enhanced by maintenance treatment. |
|---|
| DOI: | doi:10.3390/cancers13184706 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers13184706 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/13/18/4706 |
|---|
| | DOI: https://doi.org/10.3390/cancers13184706 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | lenalidomide maintenance |
|---|
| | multiple myeloma |
|---|
| | salvage autologous stem cell transplantation |
|---|
| | salvage high-dose chemotherapy |
|---|
| K10plus-PPN: | 1777668840 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma / Bärtsch, Marc-Andrea [VerfasserIn]; 20 September 2021 (Online-Ressource)
